GlassScriptPhysician profile
Eldad S Bialecki
NPI 1003952458
$19,238.38
in general payments reported to CMS, 2019-2025
34 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,309 · 2020: $2,000 · 2021: $4,860 · 2022: $2,590 · 2023: $2,731 · 2024: $3,013 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,379 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,379.41 |
| Education | $100.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,313.42 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,254.22 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Nestle Healthcare Nutrition INC. | $2,160.05 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,888.06 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,840.16 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $1,086.93 | 2019-2025 | |
| Celgene Corporation | $603.14 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $570.62 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $470.78 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $440.52 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $393.52 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $370.97 | 2019-2022 | |
| Qol Medical, LLC | $369.98 | 2019-2025 | Sucraid, Sucraid |
| Ucb, INC. | $340.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $292.32 | 2019-2024 | Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $273.12 | 2020-2023 | Avsola, Amjevita |
| Genzyme Corporation | $216.34 | 2023-2025 | |
| Ardelyx, INC. | $213.32 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $167.41 | 2020-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $165.26 | 2024-2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $148.22 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $128.86 | 2019-2023 | Rebyota |
| Echosens North America, INC. | $106.24 | 2024-2025 | Fibroscan, Fibroscan |
| Madrigal Pharmaceuticals | $87.36 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $66.72 | 2021 | |
| Shire North American Group INC | $49.10 | 2019 | |
| Alfasigma USA, INC. | $46.04 | 2020 | |
| Capsovision, INC. | $30.14 | 2024 | Capsocam Plus |
| Shionogi INC | $30.07 | 2019 | |
| Organon LLC | $28.06 | 2023 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $26.81 | 2024-2025 | Voquezna |
| Dova Pharmaceuticals | $25.74 | 2019 | |
| Exact Sciences Corporation | $21.83 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldad Bialecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.